Project Grant R43HG013069
Award Date
5/1/23
Completion Date
10/30/23
Dollars Obligated
$695K
Federal Agency
National Human Genome Research Institute
Federal Grant Program
93.172
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92121, USA
Similar Awards
The Alida Biosciences Inc. was awarded a $765,105 Project Grant from the National Institutes of Health National Human Genome Research Institute under the Human Genome Research federal grant program (CFDA 93.172) on August 17, 2021 to complete work by February 28, 2022. The grant funds the development of a new approach to analyze RNA modifications across entire transcriptomes in a multiplexed reaction at near single-base resolution. Currently available methods either lack sequence context or...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) provides $350,000 to Electronic Biosciences, Inc., a small biotechnology company, to develop a novel technology for high-accuracy sequencing of the RNA modifications pseudouridine (Ps) and N6-methyladenosine (M6A). The project aims to merge the company's nanopore-based sequencing platform with innovative bisulfite adduct methodology...
This $256,000 National Science Foundation Engineering grant supports the development of an easy RNA adenylation method for deep sequencing of picogram RNA samples with high resolution. Specifically, Ezrabio Inc. will develop a versatile and cost-effective library construction technology that enables protein translation monitoring on a variety of biological samples. The proposed technology relies on a novel enzyme system capable of 5' adenylation and 3' polyadenylation of RNA fragments to...
This Project Grant award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $303,445.00 to Endura Therapeutics Inc. to develop a next-generation sequencing platform for discovering small molecules that can modulate RNA and potentially treat diseases currently lacking treatment options. The project aims to establish an assay to detect RNA-drug interactions and identify RNA structures amenable to small molecule...
This Project Grant award from the National Human Genome Research Institute (NHGRI), under the Human Genome Research program (CFDA 93.172), is for the development of an exhaustive de novo RNA sequencing method using next-generation mass spectrometry (NGMS-seq). The $215,088 award to Directseq Biosciences, Inc. aims to 1) further advance NGMS-seq to completely sequence all RNA species in a sample, including comprehensive identification and quantification of RNA modifications, and 2) test the...
This $382,801 federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to develop a new class of artificial RNA-based organelles, or "RNA condensates," that can provide spatial and temporal control over molecules within living cells. The key products and services to be delivered under this 5-year award include: Developing methods to optimize the sequence and structure of RNA...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) award of $274,947 to Lattice Therapeutics Inc. supports the development of a customizable, next-generation RNA delivery particle. The project aims to validate the ability of an engineerable protein nanoparticle platform to efficiently and specifically deliver RNA cargoes to target cancer cells. Key objectives include in vitro evaluation of RNA...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) provides $700,000 in funding to Mirimus, Inc. to support the creation of next-generation RNA interference (RNAi) therapeutics and an in vivo model for evaluating their efficacy and biodistribution. The key products and services to be delivered under this award include: 1) Generating optimized small interfering RNAs (siRNAs) and...
This National Science Foundation (NSF) Project Grant, awarded under the Biological Sciences program (CFDA 47.074), provides $750,000 to Stanford University to develop new technologies for studying RNA, the essential molecules that carry genetic information and play crucial roles in cell functions. The key products and services to be delivered under this 3-year award include: Creating non-destructive methods to directly study RNA localization and interactions within living cells, achieving...
The National Institute of General Medical Sciences (NIGMS) awarded a $307,257 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to SXRNA Technologies, Inc. The funding supports the development of SXRNA-SELECT, a rapid cloning technology that aims to decrease the time required to clone mammalian cells and increase protein yields for biotherapeutic production. Through this Phase I effort, SXRNA Technologies, in collaboration with the University at Albany-SUNY,...